tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

Alkermes Plc

ALKS
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
43.215USD
-0.075-0.17%
์‹œ์žฅ ์šด์˜ ์‹œ๊ฐ„ย 09/23, 09:37๏ผˆET๏ผ‰
7.25B์‹œ๊ฐ€์ด์•ก
46.48P/E TTM

Alkermes Plc ์ •๋ณด ํšŒ์‚ฌ

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Alkermes Plc ํ”„๋กœํ•„

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ ALKS
ํšŒ์‚ฌ ์ด๋ฆ„Alkermes Plc
์ƒ์žฅ์ผJul 16, 1991
CEOPops (Richard F)
์ง์› ์ˆ˜1800
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒJul 16
์ฃผ์†ŒConnaught House
๋„์‹œDUBLIN
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€Ireland
์šฐํŽธ ๋ฒˆํ˜ธD04 C5Y6
์ „ํ™”35317728000
์›น์‚ฌ์ดํŠธhttps://www.alkermes.com/
์ข…๋ชฉ ์ฝ”๋“œ ALKS
์ƒ์žฅ์ผJul 16, 1991
CEOPops (Richard F)

Alkermes Plc์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Richard F. Pops
Mr. Richard F. Pops
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.38M
--
Mr. Richard F. Pops
Mr. Richard F. Pops
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.38M
--
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
223.42K
-0.91%
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
223.42K
-0.91%
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
106.68K
+2.75%
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
106.68K
+2.75%
Dr. Craig C. Hopkinson, M.D.
Dr. Craig C. Hopkinson, M.D.
Executive Vice President, Research and Development and Chief Medical Officer
Executive Vice President, Research and Development and Chief Medical Officer
65.39K
-6.12%
Dr. Craig C. Hopkinson, M.D.
Dr. Craig C. Hopkinson, M.D.
Executive Vice President, Research and Development and Chief Medical Officer
Executive Vice President, Research and Development and Chief Medical Officer
65.39K
-6.12%
Mr. Brian P. McKeon
Mr. Brian P. McKeon
Independent Director
Independent Director
48.54K
+9.62%
Mr. Brian P. McKeon
Mr. Brian P. McKeon
Independent Director
Independent Director
48.54K
+9.62%
๋” ๋ณด๊ธฐ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Richard F. Pops
Mr. Richard F. Pops
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.38M
--
Mr. Richard F. Pops
Mr. Richard F. Pops
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.38M
--
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
223.42K
-0.91%
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
223.42K
-0.91%
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
106.68K
+2.75%
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
106.68K
+2.75%

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Alkermes Plc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
Alkermes Plc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค: Mr. Richard F. Pops

Alkermes Plc(ALKS)์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ๋ช‡ ๊ฐœ์ž…๋‹ˆ๊นŒ?

๎™Œ
2026Q1 ๊ธฐ์ค€์œผ๋กœ, Alkermes Plc์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ์ด 783๊ณณ์ด๋ฉฐ, ์ด๋“ค์ด ๋ณด์œ ํ•œ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋Š” ์•ฝ 182.39M๋กœ ์ „์ฒด ๋ฐœํ–‰ ์ฃผ์‹์˜ 109.43%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค. ์ด๋Š” 2025Q4 ๋Œ€๋น„ -11997400.00 ์ฆ๊ฐ€ํ•œ ์ˆ˜์น˜์ž…๋‹ˆ๋‹ค.

Alkermes Plc์˜ ์ตœ๋Œ€ ์ˆ˜์ต์›์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
2026Q1 ๊ธฐ์ค€, Alkermes Plc์˜ VIVITROL ๋ถ€๋ฌธ์ด ๊ฐ€์žฅ ๋†’์€ ๋งค์ถœ์„ ๊ธฐ๋กํ–ˆ์œผ๋ฉฐ, ๊ธˆ์•ก์€ 124.45M๋กœ ์ „์ฒด ๋งค์ถœ์˜ 25.09%๋ฅผ ์ฐจ์ง€ํ–ˆ์Šต๋‹ˆ๋‹ค.
tradingkey.logo
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ